Results 241 to 250 of about 45,139 (271)
Correction to: Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. [PDF]
europepmc +1 more source
Efficacy and safety of diflunisal therapy in patients with transthyretin cardiac amyloidosis (ATTR-CA): a systematic review and meta-analysis. [PDF]
Huang W+5 more
europepmc +1 more source
Artificial intelligence-guided detection of under-recognised cardiomyopathies on point-of-care cardiac ultrasonography: a multicentre study. [PDF]
Oikonomou EK+10 more
europepmc +1 more source
Knowledge Landscape and Hotspots of Research in Transthyretin Amyloid Cardiomyopathy: A Bibliometric Analysis. [PDF]
Liu Y, Li X, Xin A, Zhang Y, Zhang J.
europepmc +1 more source
Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy and their caregivers: a <i>post hoc</i> analysis of an international survey. [PDF]
Cappelli F+10 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Transthyretin amyloid cardiomyopathy
Medicina Clínica (English Edition), 2021Transthyretin (TTR) cardiac amyloidosis is a severe, progressive, infiltrative disease caused by the deposition of TTR at cardiac level. It may be due to a genetic alteration in its hereditary form (ATTRv) or as a consequence of an age-related degenerative process (ATTRwt). Thanks to advances in imaging techniques and the possibility of achieving a non-
Pablo García-Pavía+2 more
openaire +3 more sources